XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

BACKGROUND: The aim was to compare two standard chemotherapy regimens combined with bevacizumab as first-line treatment in patients with metastatic colorectal cancer. METHODS: Patients previously untreated for metastatic disease were randomized in: group A (irinotecan, capecitabine, bevacizumab, eve...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Pectasides, Dimitrios, Papaxoinis, George, Kalogeras, Konstantine T, Eleftheraki, Anastasia G, Xanthakis, Ioannis, Makatsoris, Thomas, Samantas, Epaminondas, Varthalitis, Ioannis, Papakostas, Pavlos, Nikitas, Nikitas, Papandreou, Christos N, Pentheroudakis, George, Timotheadou, Eleni, Koutras, Angelos, Sgouros, Joseph, Bafaloukos, Dimitrios, Klouvas, George, Economopoulos, Theofanis, Syrigos, Konstantinos N, Fountzilas, George
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2012
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3466131/
https://ncbi.nlm.nih.gov/pubmed/22748098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-12-271
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados